Hitherto, no in silico study has been performed to predict the toxicity risks of Sartans or a novel class of synthetic antihypertensive drugs referred to as biSartans in the case that they target ACE2 and are repurposed to treat COVID-19. This evidence concerns the gene ACE2 and COVID-19.